Active	Status	Sponsor type	Region	Phase	Filter
14 Active 14 Inactive 28 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Tomlinson, Benjamin K
STIMULUS MDS-US, NCT04878432: : Sabatolimab Added to HMA in Higher Risk MDS	Completed	2	39	US	MBG453, sabatolimab, Azacitidine, Decitabine, INQOVI (oral decitabine)	Novartis Pharmaceuticals	Myelodysplastic Syndrome (MDS)	09/23	09/24
NCT04477291: A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS	Active, not recruiting	1	80	US	CG-806	Aptose Biosciences Inc.	Acute Myeloid Leukemia, Myelodysplastic Syndromes	12/24	05/25
NCT03955783: Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies	Completed	1	78	US	Venetoclax, Selinexor	Sanjay Mohan, Karyopharm Therapeutics Inc, AbbVie	Diffuse Large B-cell Lymphoma, Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma	09/24	09/24
SGNS70-101, NCT04227847: A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies	Recruiting	1	140	Europe, US	SEA-CD70, azacitidine, VIDAZA	Seagen Inc.	Myelodysplastic Syndrome, Acute Myeloid Leukemia	12/24	11/26
NCT05787496: A Safety, Tolerability and Efficacy Study of NC525 in Subjects with Advanced Myeloid Neoplasms	Active, not recruiting	1	63	US	NC525	NextCure, Inc.	Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia, Relapsed or Refractory Myelodysplastic Syndrome	05/25	05/25
Ignatz-Hoover, James
No trials found